据HoldingsChannel报道，雷曼-德拉菲洛金融资源有限责任公司在第一季度将其持有的辉瑞股票头寸提高了0.3%。该基金持有这家生物制药公司215,385股股票，在此期间又购买了625股。辉瑞在雷曼-德拉菲罗金融资源有限责任公司的投资组合中约占3.1%，使该股成为其第八大持股。截至最近提交给美国证券交易委员会的文件，雷曼金融资源公司持有的辉瑞股份价值11,150,000美元。
热门资讯> 正文
雷曼-德拉菲洛金融资源有限责任公司收购辉瑞625%的股份。
2022-07-05 20:31
Lehman & Derafelo Financial Resources LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.3% during the 1st quarter, HoldingsChannel reports. The fund owned 215,385 shares of the biopharmaceutical company's stock after purchasing an additional 625 shares during the period. Pfizer comprises approximately 3.1% of Lehman & Derafelo Financial Resources LLC's portfolio, making the stock its 8th largest holding. Lehman & Derafelo Financial Resources LLC's holdings in Pfizer were worth $11,150,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. McGuire Investment Group LLC bought a new position in Pfizer during the 4th quarter worth $237,000. Apella Capital LLC raised its position in Pfizer by 1.6% during the 4th quarter. Apella Capital LLC now owns 14,073 shares of the biopharmaceutical company's stock worth $831,000 after purchasing an additional 218 shares during the last quarter. Koshinski Asset Management Inc. raised its position in Pfizer by 7.2% during the 4th quarter. Koshinski Asset Management Inc. now owns 58,568 shares of the biopharmaceutical company's stock worth $3,458,000 after purchasing an additional 3,911 shares during the last quarter. Stratos Wealth Partners LTD. raised its position in Pfizer by 4.7% during the 4th quarter. Stratos Wealth Partners LTD. now owns 246,869 shares of the biopharmaceutical company's stock worth $14,578,000 after purchasing an additional 11,093 shares during the last quarter. Finally, Fundamentun LLC raised its position in Pfizer by 4.8% during the 4th quarter. Fundamentun LLC now owns 163,502 shares of the biopharmaceutical company's stock worth $9,655,000 after purchasing an additional 7,538 shares during the last quarter. 66.50% of the stock is currently owned by institutional investors.
其他几家对冲基金和其他机构投资者最近也增持或减持了该股。McGuire Investment Group LLC在第四季度购买了价值23.7万美元的辉瑞新头寸。Apella Capital LLC在第四季度将其在辉瑞的头寸提高了1.6%。Apella Capital LLC现在持有这家生物制药公司14,073股股票，价值831,000美元，上个季度又购买了218股。Koshinski Asset Management Inc.在第四季度将其在辉瑞的头寸提高了7.2%。Koshinski Asset Management Inc.现在持有这家生物制药公司58,568股股票，价值3,458,000美元，该公司在上个季度又购买了3,911股股票。Stratos Wealth Partners Ltd.在第四季度将其在辉瑞的头寸提高了4.7%。Stratos Wealth Partners Ltd.现在拥有246,869股这家生物制药公司的股票，价值14,578,000美元，在上个季度又购买了11,093股。最后，FunDamentun LLC在第四季度将其在辉瑞的头寸提高了4.8%。Fundamentun LLC现在持有这家生物制药公司163,502股股票，价值9,655,000美元，此前在上个季度又购买了7,538股。66.50%的股票目前由机构投资者持有。
Get
到达
Pfizer
辉瑞公司
alerts:
警报：
In other news, SVP Jennifer B. Damico sold 4,218 shares of the business's stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the transaction, the senior vice president now owns 10,846 shares in the company, valued at approximately $585,250.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the company's stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the transaction, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock worth $2,075,003 in the last 90 days. Company insiders own 0.05% of the company's stock.
在其他新闻方面，高级副总裁詹妮弗·B·达米科在6月7日星期二的一笔交易中出售了4218股该公司的股票。这只股票的平均售价为53.96美元，总价值为227,603.28美元。交易完成后，高级副总裁总裁现在拥有该公司10846股，价值约585,250.16美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的，可以通过这个链接获得。还有，执行副总裁小威廉·R·卡拉佩齐。在5月12日星期四的一次交易中出售了32,908股该公司的股票。这些股票的平均价格为50美元，总价值为1,645,400.00美元。交易完成后，执行副总裁总裁现在拥有该公司38,146股，价值约1,907,300美元。此次拍卖的披露信息可在此处找到。在过去的90天里，内部人士总共卖出了41,126股公司股票，价值2,075,003美元。公司内部人士持有该公司0.05%的股份。
PFE stock opened at $52.31 on Tuesday. The company has a market capitalization of $293.51 billion, a P/E ratio of 12.00, a price-to-earnings-growth ratio of 0.63 and a beta of 0.73. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. Pfizer Inc. has a 52-week low of $38.93 and a 52-week high of $61.71. The business has a 50-day simple moving average of $50.73 and a two-hundred day simple moving average of $51.98.
周二，PFE股价开盘报52.31美元。该公司市值为2,935.1亿美元，市盈率为12.00，市盈率为0.63，贝塔系数为0.73。该公司的负债权益比率为0.43，速动比率为1.13，流动比率为1.39。辉瑞公司股价跌至38.93美元的52周低点和61.71美元的52周高点。该业务的50日简单移动均线切入位在50.73美元，200日简单移动均线切入位在51.98美元。
Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.66 by ($0.04). The company had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. Pfizer's revenue for the quarter was up 76.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 6.63 earnings per share for the current fiscal year.
辉瑞(NYSE：PFE-GET Rating)最近一次发布季度收益报告是在5月3日，星期二。这家生物制药公司公布的季度每股收益(EPS)为1.62美元，低于分析师普遍预期的1.66美元(0.04美元)。该公司本季度营收为256.6亿美元，而分析师预期为247.3亿美元。辉瑞的净利润率为26.97%，股本回报率为38.29%。辉瑞本季度营收同比增长76.8%。去年同期，该公司公布的每股收益为0.93美元。卖方分析师预计，辉瑞公司本财年每股收益将达到6.63美元。
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, July 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.06%. Pfizer's payout ratio is presently 36.70%.
该公司最近还宣布了季度股息，将于9月6日(星期二)支付。6月29日(星期三)登记在册的股东将获得0.40美元的股息。本次股息除息日期为7月28日(星期四)。这意味着年化股息为1.60美元，股息收益率为3.06%。辉瑞目前的派息率为36.70%。
Several brokerages recently issued reports on PFE. Barclays set a $52.00 target price on Pfizer in a research report on Monday, June 27th. SVB Leerink initiated coverage on Pfizer in a research report on Monday, May 23rd. They issued a "market perform" rating and a $55.00 price objective for the company. Wells Fargo & Company lowered their price objective on Pfizer from $60.00 to $55.00 in a research report on Wednesday, May 4th. Berenberg Bank set a $50.00 price objective on Pfizer in a research report on Friday, May 27th. Finally, Citigroup lifted their price objective on Pfizer from $46.00 to $57.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 5th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $57.26.
几家券商最近发布了关于PFE的报告。巴克莱在6月27日周一的一份研究报告中为辉瑞设定了52.00美元的目标价。SVB Leerink在5月23日星期一的一份研究报告中发起了对辉瑞的报道。他们对该公司的评级为“市场表现”，目标价为55美元。富国银行在5月4日星期三的一份研究报告中将辉瑞的目标价从60.00美元下调至55.00美元。贝伦贝格银行在5月27日星期五的一份研究报告中为辉瑞设定了50美元的目标价。最后，花旗集团在4月5日星期二的一份研究报告中将辉瑞的目标价从46.00美元上调至57.00美元，并给予该股“中性”评级。9名研究分析师对该股的评级为持有，10名分析师给出了买入评级，一名分析师对该公司股票给予了强烈的买入评级。根据MarketBeat.com的数据，该公司的普遍评级为“适度买入”，平均目标价为57.26美元。
Pfizer Profile (Get Rating)
辉瑞简介(获取评级)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
辉瑞在全球发现、开发、制造、营销、分销和销售生物制药产品。该公司在不同的治疗领域提供药物和疫苗，包括Premarin系列和Eiquis品牌的心血管代谢和妇女健康；Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物制品、小分子、免疫疗法和生物仿制药；舒必乐、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的无菌注射和抗感染药物以及口服新冠肺炎治疗。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- PetVivo Holdings Is A Growth Stock Worth a Look
- PVH Corp Stock Approaching Key Support Levels
- Two Pet Health Stocks To Watch And One To Avoid
- Three (3) Top-Rated Dividend Payers Worth Your Attention
- 5 Reasons to Climb Aboard Carnival Stock
- 免费获取StockNews.com关于辉瑞的研究报告
- PetVivo Holdings是一只值得一看的成长股
- PVH公司股票接近关键支撑位
- 两只需要注意的宠物健康股票和一只要避免的宠物健康股票
- 三(3)个评级最高的股息支付者值得您关注
- 登上嘉年华股票的5个理由
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
想看看其他对冲基金持有PFE吗？访问HoldingsChannel.com获取辉瑞的最新13F备案文件和内幕交易。
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
